- Fourth quarter revenue increased 14.1% over prior year quarter, in constant currency
- Upper extremity constant currency revenue growth of 22.1% led by Aequalis Ascend Flex
- Full year adjusted gross margin increased by 180 basis points to 76.0%
AMSTERDAM, The Netherlands, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Tornier N.V. (Nasdaq:TRNX), a global medical device company focused on providing surgical solutions to orthopaedic extremity specialists, reported today its financial results for the fourth quarter and full year ended December 28, 2014.
Revenue for the fourth quarter of 2014 was $92.4 million compared to fourth quarter 2013 revenue of $83.4 million, an increase of 10.8% as reported and 14.1% in constant currency. Revenue for the full year ended December 28, 2014 was $345.0 million compared to 2013 revenue of $311.0 million, an increase of 10.9% as reported and 11.2% in constant currency.
Fourth quarter 2014 revenue of Tornier’s extremities product categories totaled $77.0 million compared to $68.1 million a year ago, an increase of 13.0% as reported and 15.5% in constant currency. For the full year 2014, revenue of Tornier’s extremities product categories was $286.7 million compared to $258.0 million a year ago, an increase of 11.2% as reported and 11.5% in constant currency.
Dave Mowry, President and Chief Executive Officer of Tornier, commented, “Our fourth quarter revenue was in-line with the preliminary results we released in January and reflects the strong performance by Tornier’s global sales organization across our key products. The continued growth was led by our Aequalis Ascend Flex shoulder system and our broad ankle arthritis portfolio. Looking toward 2015, we believe we are well positioned to further improve upon sales force productivity in our dedicated upper and lower extremities teams, driven by ongoing sales rep training programs and new product launches.”
Mr. Mowry continued, “We are pleased with the consistent and steady improvement reflected in adjusted gross margin over the course of the year, which for the full year reached 76.0%. Tornier is well positioned to continue to drive gross margin expansion through additional efficiency improvement and manufacturing in-sourcing initiatives.”
The Company’s fourth quarter 2014 adjusted EBITDA, as defined in the GAAP to non-GAAP reconciliation provided later in this release, was $14.3 million, or 15.5% of reported revenue, compared to $9.2 million, or 11.0% of revenue, in the same quarter of the prior year. For the full year ended December 28, 2014, adjusted EBITDA increased to $34.0 million, or 9.8% of reported revenue, compared to $30.4 million, or 9.8% of revenue in 2013.
Fourth Quarter 2014 Revenue Highlights
Extremities
- Revenue from the upper extremities joints and trauma category was $57.5 million, an increase of 22.1% in constant currency over the same quarter in 2013. This growth was led by the Aequalis Ascend family of shoulder joint replacement products, which continued to gain global surgeon acceptance.
- Revenue from Tornier’s lower extremities joints and trauma category in the fourth quarter of 2014 reached $15.9 million, a decrease of 1.0% in constant currency. Strong sales growth from the Company’s ankle arthritis products, including the Salto, Salto-Talaris and Salto-Talaris XT total ankle arthroplasty systems, was more than offset by lower sales of core foot fixation products.
- Revenue from the sports medicine and biologics product category was $3.6 million in the fourth quarter of 2014, an increase of 1.2% in constant currency over the same quarter in 2013, reflecting a slight volume increase in the Company’s soft tissue anchor product volume, partially offset by a decline in the Company’s biologics products.
Large Joints
Constant currency revenue growth for large joints and other products was 8.1% in the fourth quarter of 2014 and was led by the Company’s hip products that benefitted from the release of new minimally invasive instrumentation in Europe late in 2013.
Geographic Revenue
On a geographic basis as compared to the fourth quarter of 2013, Tornier’s international revenue increased 8.9% as reported and 16.6% in constant currency, representing 42% of reported global revenue. Revenue in the United States increased by 12.2% and represented 58% of reported global revenue.
Fiscal Year 2015 Outlook
The following guidance assumes Tornier continues to be a standalone business for the full year of 2015. This guidance does not include any revenue or cost synergies or dis-synergies from the proposed merger with Wright Medical Group, but it does anticipate some impact from distraction related to the announcement of the pending merger, particularly in the lower extremities business.
- The Company projects 2015 constant currency revenue to be in the range of $359 to $371 million, representing a change in constant currency of 4.1% to 7.6% over last year.
- Based on current rates, foreign currency exchange rates are expected to have a negative impact of approximately $21 million dollars on full year reported revenue. 2015 reported revenue is projected to be in the range of $338.3 to $349.6 million, representing a change of (1.9%) to 1.3% over last year.
- Constant currency revenue from Tornier’s extremities product categories in 2015 is expected to be in the range of $302 to $312 million, representing growth in constant currency of 5.3% to 8.8% over last year. This growth is expected to be driven primarily by strength in upper extremities.
- The Company projects 2015 earnings per share to be in the range of ($0.65) to ($0.38) per share.
- The Company projects 2015 adjusted EBITDA to be in the range of $35 to $39 million, or 10.3% to 11.2% of reported revenue.
Conference Call
Tornier will host a conference call today at 4:30 p.m. eastern time to discuss its fourth quarter and full year 2014 financial results and its outlook for 2015. The conference call will be available to interested parties through a live audio webcast available through the Company’s website at www.tornier.com. Those without internet access may join the call from within the U.S. by dialing (877) 673-5355; outside the U.S., dial (760) 666-3805.
A telephone replay will be available for ten days following the call by dialing (855) 859-2056 for domestic participants and (404) 537-3406 for international participants. When prompted, please enter the replay pin number 73187568. For those who are not available to listen to the live webcast, the call will be archived for one year on Tornier’s website.
For full article, please click here.
Help employers find you! Check out all the jobs and post your resume.
